Christopher Laganke, MD
Neurology · Cullman, ALNPI 1811931546
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $506,982 of the $710,612 with a category attached, or 71.3%. 60 manufacturers reported payments, led by EMD Serono, Inc. at 27.5% of the total. Among neurology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,262 payments — averaging $314.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$196K
- Biogen$169K
- Sanofi$60K
- Sanofi-aventis U.S. LLC$43K
- Ares Trading SA$41K
- TG Therapeutics, Inc.$38K
- plus $164K from 54 others
Across 535 payments — averaging $9663.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2M
- Genentech, Inc.$1.1M
- Sanofi$972K
- Biogen$519K
- TG Therapeutics, Inc.$216K
- Alkermes, Inc.$99K
- plus $233K from 5 others
What the payments were for
- Consulting fees$136,05519%
- Speaking & faculty fees$506,98271%
- Travel & lodging$33,0505%
- Food & beverage$31,5034%
- Education$2890%
- Gifts$2,7330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$710,612 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 28 | $2,155,444 |
| ZeposiaOzanimod Hydrochloride | 200 | $1,969,517 |
| MayzentSiponimod | 137 | $1,406,814 |
| AmpyraDalfampridine | 201 | $1,261,286 |
| Kesimpta PenOfatumumab | 96 | $875,083 |
| BetaseronInterferon Beta-1b | 64 | $761,629 |
| AubagioTeriflunomide | 61 | $567,730 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 78 | $557,351 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 85 | $514,976 |
| GilenyaFingolimod Hcl | 44 | $463,995 |
| Nurtec OdtRimegepant Sulfate | 263 | $434,352 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 51 | $428,719 |
| Teriflunomide | 235 | $403,371 |
| UbrelvyUbrogepant | 294 | $390,196 |
| Dalfampridine ErDalfampridine | 965 | $387,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad | $195,596 | $2,155,44428 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $19,054 | $1,969,517200 claims |
| NovartisMayzent, Gilenya | $20,421 | $1,870,809181 claims |
| Acorda Therapeutics, IncAmpyra | $600 | $1,261,286201 claims |
| AbbVieUbrelvy, Qulipta, Vraylar, Linzess | $18,952 | $1,038,270916 claims |
| PfizerNurtec Odt, Octagam | $135 | $752,281326 claims |
| BiogenVumerity, Tecfidera, Tysabri | $168,542 | $695,58782 claims |
| SanofiAubagio | $60,190 | $567,73061 claims |
| Grifols USA, LLCGamunex-C | $169 | $557,35178 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Vyvanse | $289 | $491,075533 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $146 | $373,071216 claims |
| Cycle Pharmaceuticals IncTascenso Odt | $146 | $289,25121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 neurology providers in Alabama.
Other neurology in Cullman
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Emily RiserBirmingham$231K
- Nojan ValadiOpelika$219K
- Charles MarkleMobile$212K
- Timothy PrestleyTuscaloosa$210K
- William KilgoMobile$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.